Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer

This study has been withdrawn prior to enrollment.
National Cancer Institute (NCI)
AVEO Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Roswell Park Cancer Institute Identifier:
First received: January 15, 2013
Last updated: April 10, 2017
Last verified: April 2017
This clinical trial studies tivozanib before surgery in treating patients with localized kidney cancer. Tivozanib may stop the growth of tumor cells by blocking some of the growth factors needed for cell growth.

Condition Intervention
Stage II Renal Cell Cancer
Stage III Renal Cell Cancer
Drug: tivozanib
Procedure: therapeutic conventional surgery

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Pilot Clinical Trial of Neoadjuvant Tivozanib in Localized Renal Cell Carcinoma

Resource links provided by NLM:

Further study details as provided by Roswell Park Cancer Institute:

Primary Outcome Measures:
  • Feasibility of conducting a trial of tivozanib in terms of patients completing 2 courses of tivozanib [ Time Frame: Up to 30 days after surgery ]

Secondary Outcome Measures:
  • Short-term efficacy defined as a composite of presence of partial response/stable disease/complete response assessed radiographically and correlated with the nephrectomy specimen per the Response Evaluation Criteria in Solid Tumors (RECIST) criteria [ Time Frame: Up to 30 days after surgery ]
    Response rate will be examined using the sample proportion and corresponding 95% confidence interval.

  • Incidence of adverse events evaluated using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 [ Time Frame: Up to 30 days after surgery ]

Enrollment: 0
Actual Study Start Date: March 14, 2013
Study Completion Date: December 2, 2013
Primary Completion Date: June 14, 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment (tivozanib and surgery)
Patients receive tivozanib PO QD on days 1-21. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. 25 days after completion of tivozanib, patients undergo curative nephrectomy.
Drug: tivozanib
Given PO
Other Names:
  • AV-951
  • oral VEGF receptor tyrosine kinase inhibitor AV-951
Procedure: therapeutic conventional surgery
Undergo nephrectomy

Detailed Description:


I. To assess the feasibility of conducting a trial of tivozanib in the neoadjuvant setting of localized (completely resectable) renal cell cancer (RCC).


I. To evaluate the safety of tivozanib in the neoadjuvant setting. II. To compare the tissue before and after tivozanib for pharmacodynamic purposes (tumor infiltrating lymphocytes, myeloid derived suppressor cells, necrosis in the primary tumor after exposure to tivozanib).

III. To assess the overall response rate of tivozanib in primary tumors and correlate the radiographic changes, if any, to histo-pathological changes in the pathology specimen post-nephrectomy.

IV. To compare the various growth factors (vascular endothelial growth factor [VEGF], interleukin-8 [IL-8], placenta growth factor [P1GF]) at baseline and post treatment.

V. To assess the nephrectomy rate after applying neoadjuvant tivozanib in this primarily resectable RCC population.


Patients receive tivozanib orally (PO) once daily (QD) on days 1-21. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. 25 days after completion of tivozanib, patients undergo curative nephrectomy.

After completion of study treatment, patients are followed up at 30 days.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Biopsy proven non-metastatic clear cell RCC, as per radiographic studies is T2 - T3a based on the American Joint Committee on Cancer (AJCC) 6th edition criteria
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2
  • Hemoglobin >= 10 gm/dL
  • Absolute neutrophil count (ANC) >= 1.5 X 10^9/L
  • Platelets >= 100 X 10^9/L
  • Total bilirubin < 1.5 X upper limit of normal (ULN)
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 X ULN
  • International normalization ratio (INR) < 1.5
  • Activated partial thromboplastin time (aPTT) < 1.2 X ULN
  • Serum creatinine < 1.5 mg/dL or if >= 1.5 mg/dL: calculated creatinine clearance (CrCL) > 30 mL/min based on Cockroft-Gault formula
  • Must have the ability to swallow and retain oral medication
  • Patients of childbearing potential must agree to use acceptable contraceptive methods (e.g., double barrier) during treatment
  • Patient or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure

Exclusion Criteria:

  • Pregnant or nursing female patients
  • Unwilling or unable to follow protocol requirements
  • Any condition which in the Investigator's opinion deems the patient an unsuitable candidate to receive tivozanib (solitary kidney, multiple tumors in the same or contralateral kidney)
  • Not a candidate for surgery
  • Received an investigational agent within 30 days prior to enrollment
  • Non-clear cell or sarcomatoid histology
  • Patients with metastatic disease at presentation
  • Prior therapy with tyrosine kinase inhibitor for RCC
  • A second primary malignancy (except squamous and basal cell carcinoma of skin) in the past 3 years
  • Active or chronic infections
  • Significant cardiovascular disease, including:

    • Clinically symptomatic left ventricular failure
    • Uncontrolled hypertension: systolic blood pressure of > 150 mmHg or diastolic blood pressure of > 100 mmHg documented on 2 consecutive measurements taken at least 24 hours apart
    • Myocardial infarction, severe angina, or unstable angina within 6 months prior to administration of first dose of tivozanib
    • History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation)
    • Cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation that is well controlled with anti-arrhythmic medication)
    • Coronary or peripheral artery bypass graft within 6 months of screening
  • History of coronary artery disease or peripheral arterial disease
  • History of stroke or carotid endarterectomy
  • Patients who are taking cytochrome P450 system (CYP)3A4 inducers are excluded; patients taking CYP3A4 inducers that can be safely replaced with another agent may be enrolled after a 5 day washout period
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01769885

Sponsors and Collaborators
Roswell Park Cancer Institute
National Cancer Institute (NCI)
AVEO Pharmaceuticals, Inc.
Principal Investigator: Saby George Roswell Park Cancer Institute
  More Information

Responsible Party: Roswell Park Cancer Institute Identifier: NCT01769885     History of Changes
Other Study ID Numbers: I 220412
NCI-2012-03185 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
P30CA016056 ( US NIH Grant/Contract Award Number )
Study First Received: January 15, 2013
Last Updated: April 10, 2017

Additional relevant MeSH terms:
Carcinoma, Renal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases processed this record on April 24, 2017